Research Study Summary
An Open-Label Trial Of Oral Selegiline 5 Or 10 Mg And Tadalafil 2.5 Mg Co-Administration To Male Patients With Parkinson's Disease And Moderate Erectile Dysfunction.
The purpose of this study is to see if selegiline and tadalafil (generic for Cialis®) results in an improvement in Erectile dysfunction (ED) in male patients with Parkinson's disease (PD) and moderate ED. Male PD patients who have an incomplete response to tadalafil alone will be given both medications to see if the addition of selegiline improves ED symptoms more than tadalafil alone. It is common practice for a medical doctor to prescribe these two drugs to a patient like you. However, there have been no studies conducted to examine the effects of these medications when taken together.
Selegiline is normally prescribed for PD patients that are taking carbidopa/levodopa who are not receiving complete benefit from carbidopa/levodopa.
Tadalafil is normally prescribed to men who have erectile dysfunction and/or benign prostatic hyperplasia (BPH).
To Learn more
CW ID: 200439
Date Last Changed:
March 8, 2016
Clinical Trial Snapshot
- 40 to 64 Years
- Overall Status
- Sagene Pharmaceuticals
- Facility Type
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.